Ouvry P, Allaert F-A, Desnos P, Hamel-Desnos C
Cabinet d'angiologie, 9 rue Jules Ferry, Dieppe, France.
Eur J Vasc Endovasc Surg. 2008 Sep;36(3):366-70. doi: 10.1016/j.ejvs.2008.04.010. Epub 2008 Jun 3.
To compare the relative efficacy of polidocanol (Aetoxisclerol, Kreussler, Germany) when used as a foam or liquid in the treatment of saphenous incompetence.
Multicentre, prospective, randomised controlled trial conducted in patients with incompetence of the great saphenous vein (GSV) with a truncal diameter of 4-8 mm. The great saphenous vein was injected using a single injection 2-2.5 ml of either 3% polidocanol or sclerosant foam containing one-fifth 3% polidocanol to four-fifths air (DSS technique). Clinical assessments and duplex ultrasound scanning were performed after 3 weeks and then every 6 months for 2 years. No re-injection was performed irrespective of the immediate result. The main outcome measure was elimination of GSV reflux.
Ninety-five patients participated in the study, 47 were randomised to the foam sclerosant group and 48 to the liquid group. No significant difference between the 2 groups was found regarding sex, age, height, weight and saphenous vein diameter. At 3 weeks, complete elimination of reflux was obtained in 17 of the 48 patients (35%) who received liquid sclerotherapy, versus 40 of the 47 subjects (85%) in the foam group (p<0.001, Chi squared). The incidence of immediate venous spasm and the length of the sclerotic reaction, occlusion measured by echography, were significantly greater in the foam group. There was no difference in the incidence of ecchymosis, inflammatory reactions or other side effects. Follow-up of 6, 12, 18 and 24 months confirms our early results published in 2003. In total only 5 patients were lost to follow-up at 2 years (all of them were in foam group). These patients were included in the final outcome analysis as treatment failures (success rates at 2 years: 53% in foam group and 12% in liquid group).
The sclerosant foam used in this study was more than twice as effective as the liquid from which the foam was prepared.
比较聚多卡醇(德国克吕斯勒公司生产的Aetoxisclerol)作为泡沫剂或液体用于治疗大隐静脉功能不全时的相对疗效。
对大隐静脉(GSV)功能不全且主干直径为4 - 8mm的患者进行多中心、前瞻性、随机对照试验。采用单一注射法向大隐静脉内注射2 - 2.5ml 3%聚多卡醇或含五分之一3%聚多卡醇和五分之四空气的硬化剂泡沫(DSS技术)。3周后进行临床评估和双功超声扫描,之后每6个月进行一次,持续2年。无论即时结果如何,均不进行再次注射。主要观察指标为大隐静脉反流的消除情况。
95例患者参与研究,47例随机分为泡沫硬化剂组,48例分为液体组。两组在性别、年龄、身高、体重和大隐静脉直径方面无显著差异。3周时,接受液体硬化治疗的48例患者中有17例(35%)反流完全消除,而泡沫剂组47例患者中有40例(85%)反流完全消除(p<0.001,卡方检验)。泡沫剂组即时静脉痉挛的发生率以及硬化反应的长度(通过超声检查测量的闭塞情况)显著更高。瘀斑、炎症反应或其他副作用的发生率无差异。6、12、18和24个月随访结果证实了我们2003年发表的早期结果。2年时总共只有5例患者失访(均在泡沫剂组)。这些患者作为治疗失败纳入最终结果分析(2年成功率:泡沫剂组为53%,液体组为12%)。
本研究中使用的硬化剂泡沫的疗效是制备该泡沫的液体的两倍多。